Targeted re-radiation for prostate cancer recurrence in one area
Part of Cancer, Kidney & urinary clinical trials.
This study tests a focused radiation treatment (SBRT) to a small, clearly identified spot in the prostate for men whose prostate cancer has come back after prior external beam radiation. It may help control cancer while limiting radiation to the rest of the prostate and nearby organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished external beam radiation (EBRT) at least 4 years ago, or at least 5 years ago if you also had hormone therapy (ADT) around that time.
- Your recurrence is confined to less than one half (less than or equal to one lobe) of the prostate on specialized scans (PSMA scan and prostate MRI).
- You must have a biopsy that proves the cancer is back, and the positive samples must come from the same suspicious area seen on the scans.
- You should have an expected lifespan of about 10 years or more.
- Your PSA level must be under 10.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
This trial tests a precise type of radiation (called SBRT) to the prostate bed for men whose PSA starts rising after prostate removal surgery. It aims to see if this targeted approach can effectively treat the recurrence without needing long-term hormone therapy.
This trial tests targeted radiation (SBRT) for people whose rectal cancer has come back in the pelvis and cannot be surgically removed. The goal is to see if this focused radiation can control the tumor with fewer side effects.
This trial uses advanced imaging to pinpoint where prostate cancer has come back after surgery, then delivers focused radiation doses to those spots while reducing radiation to healthy tissue. The goal is to control the cancer while minimizing side effects.
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
Hear when a new Locally Recurrent Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.